Literature DB >> 18981559

Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder.

Muhammad Wasif Saif.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18981559

Source DB:  PubMed          Journal:  JOP        ISSN： 1590-8577


× No keyword cloud information.
  3 in total

Review 1.  Metabolism considerations for kinase inhibitors in cancer treatment.

Authors:  Derek R Duckett; Michael D Cameron
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

2.  Development of Nanocochleates Containing Erlotinib HCl and Dexketoprofen Trometamol and Evaluation of In Vitro Characteristic Properties.

Authors:  Özlem Çoban; Zelihagül Değim
Journal:  Turk J Pharm Sci       Date:  2018-04-02

3.  Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial.

Authors:  Antonio Saviano; François Habersetzer; Joachim Lupberger; Pauline Simo-Noumbissie; Catherine Schuster; Michel Doffoël; Catherine Schmidt-Mutter; Thomas F Baumert
Journal:  Clin Transl Gastroenterol       Date:  2022-06-01       Impact factor: 4.396
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.